Clarivate™ has revealed the annual list of Highly Cited Researchers™ 2024, curated by its experts at the Institute for Scientific…
Josep Tabernero
The phase 3 BEACON CRC trial demonstrated that treatment with the BRAF inhibitor encorafenib plus anti-EGFR monoclonal antibody cetuximab, with…
Announced by the European Medicines Agency (EMA) last month, June 21, the highly selective and potent VEGFR inhibitor fruquintinib has…
First results of two multi-center international Phase 1 dose-escalation and -expansion clinical trials of novel T-cell bispecific antibody cibisatamab as…
Celebrated today at the General Assembly of the Organisation of European Cancer Institutes (OECI), VHIO’s Director and Head of the…
On April 3, the VII National Medicine Awards organized by the magazine El Suplemento were presented. Dr. Josep Tabernero, director…
Josep Tabernero, Director of VHIO, has been awarded as a Fellow of the American Society of Clinical Oncology (FASCO). This…
Vall d’Hebron Barcelona Hospital Campus has celebrated its first PhD Day, a whole day of scientific activities created for and…
Clarivate, a global leader in connecting people and organizations to intelligence to transform the world, has revealed its list of…
Josep Tabernero, Director of the Vall d’Hebron Institute of Oncology (VHIO) has been appointed chairman of the European consortium Cancer…
